Objectives: The population of the Saguenay-Lac-St-Jean (SLSJ) region (Quebec, Canada) is known to have a relatively high prevalence of certain hereditary disorders, which can be explained by the consequences of founder effects. This study aims at providing new insights on the origins and subregional stratification of these founder effects. Methods: The genealogies of 300 individuals were reconstructed and analyzed using the BALSAC population register. Results: Inbreeding and kinship levels are higher in Lower Saguenay than in Upper Saguenay and Lac-St-Jean. The population of Lower Saguenay also distinguishes itself because of a fewer number of distinct ancestors. Conclusion: Beyond the genetic features that characterize the whole region, SLSJ also displays intraregional variability. Thus it is important to take into account the settlement patterns and the demographic history of this population for a better appraisal of its contemporary genetic structure.

1.
Pouyez C, Lavoie Y: Les Saguenayens, introduction à l’histoire des populations du Saguenay XVIe–XXe siècles. Québec, Presses de l’Université du Québec, 1983.
2.
Gauvreau D, Guerin M, Hamel M: De Charlevoix au Saguenay: mesures et caractéristiques du mouvement migratoire avant 1911; in Bouchard G, DeBraekeleer M (eds): Histoire d’un génome. Québec, Presses de l’Université du Québec, pp 145–161.
3.
Vézina H: Démographie génétique et maladies héréditaires au Québec: l’état des recherches. Cah Que Demogr 1996;25:293–322.
4.
Scriver C: Human genetics: Lessons from Quebec populations. Annu Rev Genomics Hum Genet 2001;2:96–101.
5.
Heyer E, Tremblay M: Variability of the genetic contribution of Quebec population founders associated to some deleterious genes. Am J Hum Genet 1995;56:970–978.
6.
Heyer E, Tremblay M, Desjardins B: Seventeenth-century European origins of hereditary diseases in the Saguenay population. Hum Biol 1997;69:209–224.
7.
Mootha VK, Lepage P, Miller K, Bunkerborg J, Reich M, Hjerrild M, Delmonte T, Villeneuve A, Sladek R, Xu F, Mitchell G, Morin C, Mann M, Hudson TJ, Robinson B, Rioux JD, Lander ES: Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc Natl Acad Sci USA 2003;100:605–610.
8.
Bouchard G, DeBraekeleer M: Pourquoi des maladies héréditaires? Population et génétique au Saguenay-Lac-St-Jean. Sillery, Septentrion, 1992.
9.
Mathieu J, DeBraekeleer M, Prevost C: Genealogical reconstruction of myotonic dystrophy in the Saguenay-Lac-Saint-Jean area (Quebec, Canada). Neurology 1990;40:839–842.
10.
Daigneault J, Aubin G, Simard F, DeBraekeleer M: Incidence of cystic fibrosis in Saguenay-Lac-St.-Jean (Quebec, Canada). Hum Biol 1992;64:115–119.
11.
Corporation de recherche et d’action sur les maladies héréditaires, Chicoutimi. http://www.coramh.org/coramh. Consulted on 4 Feb 2004.
12.
Bouchard G, Roy R, Casgrain B, Hubert M: Computer in human sciences: From family reconstitution to population reconstruction; in Nissan E, Schmidt KM (eds): From Information to Knowledge: Conceptual and Content Analysis by Computer. Oxford, Intellect, 1995, pp 201–227.
13.
Bouchard G: Projet BALSAC. Rapport annuel 2002–2003. Chicoutimi, Document de l’IREP, 2003. http://www.uqac.uquebec.ca/balsac/.
14.
Légaré J: A population register for Canada under the French Regime: Context, scope, content, and applications. Can Stud Popul 1988;15:1–16.
15.
Bouchard G: The processing of ambiguous links in computerized family reconstruction. Hist Methods 1986;19:9–19.
16.
Jomphe M, Tremblay M, Vézina H: Analyses généalogiques à partir du fichier RETRO. Document du Projet BALSAC No. I-C-215, 2002.
17.
Jetté R: Traité de généalogie. Montréal, Les Presses de l’Université de Montréal, 1991.
18.
Cazes MH, Cazes P: Comment mesurer la profondeur généalogique d’une ascendance? Population 1996;51:117–140.
19.
Wright S: Coefficient of inbreeding and relationship. Am Nat 1922;56:330–338.
20.
Malecot G: Les mathématiques de l’hérédité. Paris, Masson, 1948.
21.
DeBraekeleer M, Bouchard G, Gradie M: Consanguinité et parenté au Saguenay; in Bouchard G, Debraekeleer M (eds): Histoire d’un génome. Québec, Presses de l’Université du Québec, 1991, pp 323–342.
22.
Tremblay M, Jomphe M, Vézina H: Comparaison de structures patronymiques et génétiques dans la population québécoise; in Brunet G, Darlu P, Zei G: Le patronyme: histoire, anthropologie, société. Paris, CNRS Editions, Paris, 2001, pp 367–389.
23.
Lambert JF: Effet fondateur et origine de la mutation D9N du gène de la lipase lipoprotéique au sein de la population du Saguenay-Lac-St-Jean. MSc Thesis, Université du Québec à Chicoutimi/Université Laval, 2002.
24.
Roy R, Bouchard G, Declos M: La première génération de Saguenayens: provenance, apparentement, enracinement. Cah Que Demogr 1988;17:113–134.
25.
Gradie M, Jorde L, Bouchard G: Genetic structure of the Saguenay, 1852–1911: Evidence from migration and isonymy matrices. Am J Phys Anthropol 1988;77:321–333.
26.
Morissette J: La consanguinité dans la population de Charlevoix (1680–1852); in Bouchard G, DeBraekeleer M (eds): Histoire d’un génome. Québec, Presses de l’Université du Québec, 1991, pp 107–120.
27.
Vigneault A, Brisson D, Bélanger C, Gaudet D: Community genetics in Eastern Quebec: The experience of the Corporation for research and action on hereditary diseases. Community Genet 2000;3:151–155.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.